Epocrates targets OTCs with reference module

Share this article:
Epocrates targets OTCs with reference module
Epocrates targets OTCs with reference module
Epocrates introduced a new OTC drug module that will allow clinicians to access the latest information for hundreds of brand name OTC drugs from their iPhone, BlackBerry, Palm or Windows device.

Officials at the San Mateo, CA-based company note that OTC products with multiple active ingredients are very common since patients often have many symptoms to treat at once. The OTC reference module will allow physicians and pharmacists to identify specific ingredients in combination products, such as for cough and cold. For instance, an antihistamine could cause additional drowsiness or interact with blood pressure medicines.

A physician using Epocrates software could quickly find the single offending agent causing a product's contraindication, adverse reaction or drug interactions and identify an alternative.

Health providers may also use the software to uncover: drug interactions between OTC and prescription medications; safe products for pregnant women and sugar-free products for diabetics; products covered by Medicaid and select health plans for eligible patients; and medications by class such as analgesics or expectorants (cough syrups). 

Epocrates is a provider of clinical information and decision support tools to healthcare professionals and currently has more than 800,000 active subscribers worldwide, including more than one in three US physicians and 40% of US medical students.
Share this article:

Email Newsletters

More in News

House bill would speed approval once EU OKs same product

House bill would speed approval once EU OKs ...

The Speeding Access to Already Approved Pharmaceuticals Act of 2014 would require FDA to expedite the review of pharmaceuticals that are already approved by the European Union

Rep access continues to shrink

Rep access continues to shrink

Sales reps are experiencing even more limited physician access, according to a report by Chicago consultancy ZS Associates.

Allergan touts reorg, plans to lay off 13% of workforce

Allergan touts reorg, plans to lay off 13% ...

Allergan's second-quarter earnings, and a new round of cuts, are now part of the Botox maker's record as it seeks to remain independent.